1616639-03-2

Aldafermin (NGM282) is an analog of fibroblast growth factor 19. Aldafermin can be used for the research of nonalcoholic steatohepatitis (NASH)[1].

[1] Stephen A Harrison, et al. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis. Gastroenterology. 2021 Jan;160(1):219-231.e1. DOI:10.1053/j.gastro.2020.08.004